| 产品描述: | ZLY28 is the first-in-class intestinal restricted and orally active FXR and FABP1 dual modulator. ZLY28 also is a novel anti-NASH agent. ZLY28 can be used for the research of nonalcoholic steatohepatitis (NASH). |
| 体外研究: |
ZLY28 (oral; 20 mg/kg) 通过调节 NASH 小鼠模型中的脂质代谢、炎症、氧化应激和纤维化等多种发病机制显着缓解脂肪肝。 |
| 体内研究: |
ZLY28 具有合适的肝微粒体稳定性,对 FXR(EC50 = 143 nM)和 FABP1(IC50 = 2.7 μM)具有高靶向选择性< /sup>. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.922 ml |
9.608 ml |
19.216 ml |
| 5 mM |
0.384 ml |
1.922 ml |
3.843 ml |
| 10 mM |
0.192 ml |
0.961 ml |
1.922 ml |
| 50 mM |
0.038 ml |
0.192 ml |
0.384 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |